InDex Pharmaceuticals Holding AB

INDEX

SE0008966295

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 16:29:30 07/06/2024 BST			5-day change	1st Jan Change
0.538 ^SEK	+1.13%		+1.89%	+110.16%

06-07	InDex Pharmaceuticals Gets OK to Keep Nasdaq First North Growth Market Listing Amid Reverse Takeover, Uplisting Plans	MT
05-21	Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson...

InDex Pharmaceuticals Holding AB Announces Resignation of Pernilla Sandwall as Chief Operating Officer

February 13, 2022 at 08:00 pm

InDex Pharmaceuticals Holding AB (publ) announced that Chief Operating Officer Pernilla Sandwall has decided to leave the company to become CEO of WntResearch. She will continue in her current role until the end of April. The process to recruit her successor will be initiated immediately.

Latest news about InDex Pharmaceuticals Holding AB

InDex Pharmaceuticals Gets OK to Keep Nasdaq First North Growth Market Listing Amid Reverse Takeover, Uplisting Plans	06-07	MT
Global markets live: Microsoft, Roche, BMW, Nintendo, Nordson...	05-21
InDex Pharmaceuticals to Buy Flerie Invest Under Reverse Merger Plan	05-21	MT
InDex Pharmaceuticals Holding AB Approves the Election of Karl Tobieson as Board Member	05-07	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-26	CI
Index Pharmaceuticals Holding AB Announces Board Resignations	04-05	CI
InDex Pharmaceuticals CEO, CFO to Step Down as Operations Cease	03-26	MT
Index Pharmaceuticals Holding AB Announces Resignation of Johan Giléus as Deputy CEO	03-26	CI
InDex Pharmaceuticals Holding AB Announces Resignation of Jenny Sundqvist as CEO, Effective September 26, 2024	03-26	CI
InDex Pharmaceuticals Holding AB Announce Resignation of Johan Giléus as CFO, Effective September 26, 2024	03-26	CI
InDex Pharmaceuticals Launches Strategic Review Amid Decision to Stop Cobitolimod Development	02-27	MT
InDex Pharmaceuticals Holding AB Discontinues the Development of Cobitolimod	02-26	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-21	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-21	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-28	CI
InDex Pharmaceuticals Holding AB Discontinues Cobitolimod Phase III Program	11-21	CI
InDex Pharmaceuticals Holding AB Announces Composition of the Nomination Committee	30/10/23	CI
InDex Pharmaceuticals Obtains South Korean Patent for Inflammatory Bowel Disease Drug Candidate	20/10/23	MT
InDex Pharmaceuticals Holding AB Receives New Patent for Cobitolimod in South Korea	20/10/23	CI
InDex Pharmaceuticals Holding AB Announces All Patients Needed for the Cobitolimod Dose Selection Milestone Have Completed Induction Study 1 of the Phase III Program Conclude	11/10/23	CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23/08/23	CI
InDex Pharmaceuticals Holding AB Announces Positive Results from the Pharmacokinetic (PK) Study	22/08/23	CI
InDex Pharmaceuticals Holding AB Announces New Formulation Patent for Drug Candidate Cobitolimod Grants by European Patent Office	02/08/23	CI
InDex Pharmaceuticals Obtains New European Patent for Inflammatory Bowel Disease Drug	02/08/23	MT
InDex Pharmaceuticals Holding AB Announces License Agreement with Viatris Japan to Develop and Commercialize Cobitolimod in Japan	31/05/23	CI

Chart InDex Pharmaceuticals Holding AB

Duration

Period

More charts

Company Profile

InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused in pharmaceuticals development. The Company's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The Company also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohnâs disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.

Sector

Pharmaceuticals

Calendar

20/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.538 SEK

Average target price

0.535 SEK

Spread / Average Target

-0.56%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
INDEX PHARMACEUTICALS HOLDING AB	+110.16%	27.19M
ELI LILLY AND COMPANY	+45.82%	765B
JOHNSON & JOHNSON	-6.16%	354B
MERCK & CO., INC.	+19.86%	331B
ABBVIE INC.	+9.32%	299B
ASTRAZENECA PLC	+18.45%	248B
ROCHE HOLDING AG	-0.78%	219B
NOVARTIS AG	+11.88%	216B
AMGEN INC.	+5.90%	164B
PFIZER, INC.	-0.73%	162B

Other Pharmaceuticals